保德國際發展(00372.HK):附屬千洋供股遭法院禁止進行
保德國際發展(00372.HK)公布,有關擁有千洋35%股份的股東並為其董事的朱濱針對千洋及其董事就擬向千洋之股東提出千洋股份要約展開之法律訴訟,押後聆訊已於今年6月16日舉行,其中法院授出禁制令,禁止千洋進行已於5月31日在千洋董事會會議上批准之千洋供股。
該禁制令並無禁止千洋董事會召開進一步董事會會議,藉以考慮及批准千洋進行集資活動,包括但不限於由千洋進行供股及進行將來經千洋董事會批准之集資活動。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.